Table 3.
Univariate analyses of various clinical parameters in prostate cancer patients
| Parameters | Progression-Free survival | Cancer-Specific survival | Overall survival | |||
|---|---|---|---|---|---|---|
| HR (95 % CI) | P-value | HR (95 % CI) | P-value | HR (95 % CI) | P-value | |
| Age (years) | 0.958 (0.938–0.981) | <0.001 | 0.993 (0.962–1.024) | 0.641 | 1.005 (0.975–1.035) | 0.749 |
| PSA (μg/L) | 1.003 (1.002–1.004) | <0.001 | 1.003 (1.001–1.005) | 0.002 | 1.002 (1.000–1.004) | 0.029 |
| Gleason Score | <0.001 | <0.001 | <0.001 | |||
| ≤ 7 | 1 | 1 | 1 | |||
| > 7 | 2.791 (1.921–4.055) | 4.710 (2.499–8.878) | 4.998 (2.286–6.993) | |||
| Metastasis | <0.001 | <0.001 | <0.001 | |||
| No | 1 | 1 | 1 | |||
| Yes | 3.447 (2.385–4.984) | 5.893 (3.128–11.102) | 3.951 (2.331–6.696) | |||
| Risk Stratification | 0.005 | 0.058 | 0.111 | |||
| Lowintermediate | 1 | 1 | 1 | |||
| High | 4.128 (1.524–11.182) | 6.751 (0.935–48.730) | 2.560 (0.805–8.140) | |||
| Platelet (109/L) | 0.053 | 0.157 | 0.121 | |||
| < 190.50 | 1 | 1 | 1 | |||
| ≥ 190.50 | 1.414 (0.995–2.003) | 1.442 (0.869–2.394) | 1.450 (0.907–2.318) | |||
| Lymphocyte (109/L) | 0.866 (0.632–1.185) | 0.367 | 0.724 (0.454–1.153) | 0.174 | 0.775 (0.506–1.188) | 0.242 |
| PLR | 0.029 | 0.014 | 0.020 | |||
| < 117.58 | 1 | 1 | 1 | |||
| ≥ 117.58 | 1.480 (1.040–2.107) | 1.948 (1.145–3.312) | 1.781 (1.096–2.894) | |||
Abbreviations: HR hazard ratio, CI confidence interval, PSA prostate-specific antigen